Results 171 to 180 of about 15,932 (195)

Randomized Controlled Trial of Dapagliflozin for Post-Transplant Diabetes Mellitus in Renal Transplant Recipients. [PDF]

Kidney Int Rep
Lin L, Li J, Zhou J, Gao X, Lin S, Wang D, Chen P.   +6 more
europepmc   +1 more source

Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial. [PDF]

ESC Heart Fail
Zelniker TA, Paschen C, Mann C, Eigner M, Hafner-Gießauf H, Kletzmayr J, Lorenz M, Ludvik B, Stulnig T, Waller I, Werzowa J, Hödlmoser S, Hengstenberg C, Oberbauer R, Hecking M.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis

Journal of Clinical Endocrinology and Metabolism, 2020
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna   +2 more
exaly  

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Diabetes Care, 2023
Hiddo J L Heerspink, Persson Frederik, Jongs Niels   +2 more
exaly  

Dapagliflozin

Reactions Weekly, 2016
openaire   +2 more sources

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

Pharmacological Research, 2020
Donato Cappetta, Antonella De Angelis, Loreta Pia Ciuffreda   +2 more
exaly  

Dapagliflozin

Reactions Weekly, 2017
openaire   +2 more sources

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers

Diabetes Care, 2009
John P H Wilding, Paul Norwood, James F List   +2 more
exaly  

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, 2018
Dirk Müller-Wieland, Monika Kellerer, Katarzyna Cypryk   +2 more
exaly